Entospletinib,Lanraplenib
Kronos Bio,gilead
[]
$kron kronos bio continues to advance investigational syk inhibitors entospletinib and lanraplenib with new preclinical data at eha2022 congress 45 seconds delayed.
Democratizing insights.

Not investment advice.